RxDoctor Payments Data

Ali Nsair, MD

Interventional Cardiology · Los Angeles, CANPI 1366739880

Payments from drug & device makers

$260,336in general payments, 2019–2025

Across 171 payments — averaging $1522.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$95K
  • Novartis$65K
  • E.r. Squibb & Sons, L.L.C.$45K
  • AstraZeneca$27K
  • Philips North America LLC$18K
  • Livanova USA, Inc.$7K
  • plus $3K from 12 others

What the payments were for

  • Consulting fees$7,4045%
  • Speaking & faculty fees$124,69277%
  • Grants$1000%
  • Travel & lodging$24,09315%
  • Food & beverage$5,9894%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$260,336 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$77,575
Medicare patients
176
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan120$156,609
CamzyosMavacamten17$137,601
FarxigaDapagliflozin Propanediol72$80,182
EliquisApixaban36$34,200
JardianceEmpagliflozin23$21,020
BrilintaTicagrelor14$15,622
Repatha SyringeEvolocumab14$11,823
CorlanorIvabradine Hcl15$11,114
Metoprolol Succinate73$1,218
Bumetanide27$996
Midodrine Hcl12$972
Atorvastatin Calcium72$729
Carvedilol38$448
Rosuvastatin Calcium27$442
Potassium Chloride13$421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$65,345$156,609120 claims
E.r. Squibb & Sons, L.L.C.Camzyos$44,977$137,60117 claims
AstraZenecaFarxiga, Brilinta$27,302$95,80486 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →